DK1071710T3 - Genomisk sekvens for 5-lipoxygenase-aktiveringsproteinet (FLAP), polymorfe markörer deri og fremgangsmåder til påvisning af astma - Google Patents

Genomisk sekvens for 5-lipoxygenase-aktiveringsproteinet (FLAP), polymorfe markörer deri og fremgangsmåder til påvisning af astma

Info

Publication number
DK1071710T3
DK1071710T3 DK99913538T DK99913538T DK1071710T3 DK 1071710 T3 DK1071710 T3 DK 1071710T3 DK 99913538 T DK99913538 T DK 99913538T DK 99913538 T DK99913538 T DK 99913538T DK 1071710 T3 DK1071710 T3 DK 1071710T3
Authority
DK
Denmark
Prior art keywords
flap
genomic sequence
methods
activation protein
polymorphic markers
Prior art date
Application number
DK99913538T
Other languages
English (en)
Other versions
DK1071710T4 (da
Inventor
Marta Blumenfeld
Ilya Chumakov
Lydie Bougueleret
Original Assignee
Serono Genetics Inst Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27374096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1071710(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Serono Genetics Inst Sa filed Critical Serono Genetics Inst Sa
Publication of DK1071710T3 publication Critical patent/DK1071710T3/da
Application granted granted Critical
Publication of DK1071710T4 publication Critical patent/DK1071710T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
DK99913538.7T 1998-04-15 1999-04-15 Genomisk sekvens for 5-lipoxygenase-aktiveringsproteinet (FLAP), polymorfe markører deri og fremgangsmåder til påvisning af astma DK1071710T4 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8189398P 1998-04-15 1998-04-15
US9131498P 1998-06-30 1998-06-30
US12340699P 1999-03-08 1999-03-08
PCT/IB1999/000744 WO1999052942A2 (en) 1998-04-15 1999-04-15 Genomic sequence of the 5-lipoxygenase-activating protein (flap), polymorphic markers thereof and methods for detection of asthma

Publications (2)

Publication Number Publication Date
DK1071710T3 true DK1071710T3 (da) 2007-02-19
DK1071710T4 DK1071710T4 (da) 2011-12-12

Family

ID=27374096

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99913538.7T DK1071710T4 (da) 1998-04-15 1999-04-15 Genomisk sekvens for 5-lipoxygenase-aktiveringsproteinet (FLAP), polymorfe markører deri og fremgangsmåder til påvisning af astma

Country Status (11)

Country Link
US (4) US6531279B1 (da)
EP (1) EP1071710B2 (da)
JP (1) JP4472173B2 (da)
AT (1) ATE342918T1 (da)
AU (1) AU768721B2 (da)
CA (1) CA2321226C (da)
DE (1) DE69933661T3 (da)
DK (1) DK1071710T4 (da)
ES (1) ES2272061T5 (da)
PT (1) PT1071710E (da)
WO (1) WO1999052942A2 (da)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2321226C (en) * 1998-04-15 2011-06-07 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (flap), polymorphic markers thereof and methods for detection of asthma
US6537751B1 (en) * 1998-04-21 2003-03-25 Genset S.A. Biallelic markers for use in constructing a high density disequilibrium map of the human genome
US6986987B1 (en) * 1998-07-24 2006-01-17 The Uab Research Foundation Genetic polymorphism in the receptor for IgA
WO2000047771A2 (en) 1999-02-12 2000-08-17 Genset Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
KR100679349B1 (ko) * 1999-11-30 2007-02-07 아사히비루 가부시키가이샤 하면 맥주효모의 응집성 판정방법
US20020077775A1 (en) * 2000-05-25 2002-06-20 Schork Nicholas J. Methods of DNA marker-based genetic analysis using estimated haplotype frequencies and uses thereof
US7205146B1 (en) * 2000-06-14 2007-04-17 Oscient Pharmaceuticals Corporation Nucleotide and amino acid sequences relating to respiratory diseases and obesity
CN1329012A (zh) * 2000-06-21 2002-01-02 上海博德基因开发有限公司 一种新的多肽——烟酰胺腺嘌呤脱氧二核苷酸依赖性白三烯b412－羟基脱氢酶36和编码这种多肽的多核甘酸
AU2001288980B2 (en) * 2000-09-08 2005-12-01 Pig Improvement Company Uk Limited Novel PRKAG3 alleles and use of the same as genetic markers for reproductive and meat quality traits
AU2002224229B2 (en) * 2000-10-31 2007-11-29 Wouter Herman Robert Coppieters Marker assisted selection of bovine for improved milk production using diacylglycerol acyltransferase gene DGAT1
WO2002048400A1 (fr) * 2000-12-12 2002-06-20 Nagoya Industrial Science Research Institute Procede d'estimation du risque de l'expression d'effets secondaires causes par l'administration de compose metabolise, soit automatiquement, soit comme intermediaire metabolique, par l'enzyme ugt1a1
FI114483B (fi) * 2001-02-20 2004-10-29 Jurilab Ltd Oy Menetelmä kohonneen verenpaineen riskin osoittamiseksi ja sen käytöt
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
US7115726B2 (en) * 2001-03-30 2006-10-03 Perlegen Sciences, Inc. Haplotype structures of chromosome 21
WO2002086161A1 (fr) * 2001-04-19 2002-10-31 Hubit Genomix, Inc. Procede permettant d'evaluer le diplotype du genotype d'un individu
ATE441727T1 (de) * 2001-10-01 2009-09-15 Sinai School Medicine Noonansyndromgen
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AU2003219994B2 (en) * 2002-03-04 2009-04-09 The Texas A & M University System Quantitative trait loci and somatostatin
US7579147B2 (en) * 2002-05-07 2009-08-25 Wake Forest University Health Sciences Mutations in the macrophage scavenger receptor 1 gene alter risk of prostate cancer, asthma, and cardiovascular disease
US20040081653A1 (en) * 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CA2497132A1 (en) * 2002-08-30 2004-03-25 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
US7851486B2 (en) * 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
WO2004035741A2 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction; methods of treatment
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
CA2502359A1 (en) * 2002-10-17 2004-04-29 Decode Genetics Ehf. Susceptibility gene for myocardial infarction
US7507531B2 (en) * 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US20040146870A1 (en) * 2003-01-27 2004-07-29 Guochun Liao Systems and methods for predicting specific genetic loci that affect phenotypic traits
US7803538B2 (en) * 2003-06-20 2010-09-28 Aventis Pharma Sa Method for detecting Alzheimer's disease
EP1656372B1 (en) * 2003-07-30 2013-04-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
WO2005027719A2 (en) 2003-09-12 2005-03-31 Perlegen Sciences, Inc. Methods and systems for identifying predisposition to the placebo effect
EP1670445A2 (en) * 2003-09-17 2006-06-21 Decode Genetics EHF. Methods of preventing or treating recurrence of myocardial infarction
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
JP2007315752A (ja) * 2004-08-16 2007-12-06 Ajinomoto Co Inc 肝線維化ステージの判定方法
EP1951261A4 (en) * 2005-10-31 2009-06-24 Rigel Pharmaceuticals Inc PREPARATIONS AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISORDERS
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20080091730A1 (en) * 2006-09-29 2008-04-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US10546652B2 (en) 2006-09-29 2020-01-28 Gearbox Llc Computational systems for biomedical data
US8122073B2 (en) * 2006-09-29 2012-02-21 The Invention Science Fund I Computational systems for biomedical data
US20080082359A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of State Of Delaware Computational systems for biomedical data
US10095836B2 (en) * 2006-09-29 2018-10-09 Gearbox Llc Computational systems for biomedical data
US20080109484A1 (en) * 2006-09-29 2008-05-08 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US20080082271A1 (en) * 2006-09-29 2008-04-03 Searete Llc Computational systems for biomedical data
US10503872B2 (en) * 2006-09-29 2019-12-10 Gearbox Llc Computational systems for biomedical data
US20080082367A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US20080082306A1 (en) * 2006-09-29 2008-04-03 Searete Llc Computational systems for biomedical data
US7853626B2 (en) 2006-09-29 2010-12-14 The Invention Science Fund I, Llc Computational systems for biomedical data
US20080082583A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US20080082584A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US10068303B2 (en) 2006-09-29 2018-09-04 Gearbox Llc Computational systems for biomedical data
US20080082364A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
WO2008067566A1 (en) 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
CN101918552B (zh) * 2007-10-29 2012-11-21 独立行政法人理化学研究所 使用brca1相关蛋白(brap)基因内单核苷酸多态性判定炎症性疾病的方法
SG190667A1 (en) 2008-05-23 2013-06-28 Panmira Pharmaceuticals Llc 5-lipoxygenase-activating protein inhibitor
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US8568980B2 (en) 2009-01-27 2013-10-29 Mount Sinai School Of Medicine Nucleic acids, methods and kits for the diagnosis of DYT6 primary torsion dystonia
US20130261059A1 (en) * 2010-05-26 2013-10-03 The Children's Hospital Of Philadelphia Compositions and Methods for the Diagnosis and Treatment of Primary Insulin-Like Growth Factor Deficiency (PIGFD) and Idiopathic Short Stature (ISS)
LT2621526T (lt) 2010-09-29 2018-09-25 Agensys, Inc. Antikūno-vaisto konjugatai (adc), kurie jungiasi prie 191p4d12 baltymų
EP2865756A1 (en) 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
CA2938879C (en) 2014-02-04 2023-05-09 Bioscience Pharma Partners, Llc Use of flap inhibitors to reduce neuroinflammation mediated injury in the central nervous system
EP3388448B1 (en) * 2015-12-11 2022-05-04 National University Corporation Kochi University Marker for pancreatic cancer and intraductal papillary mucinous tumors
KR102527520B1 (ko) * 2020-09-16 2023-05-03 순천대학교 산학협력단 직업성 천식 진단용 조성물 및 이를 이용한 직업성 천식 진단방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2032253C (en) 1989-12-15 2000-11-28 John W. Gillard 5-lipoxygenase activating protein
US5182367A (en) * 1990-11-30 1993-01-26 Merck & Co., Inc. 5-lipoxygenase activating protein
US5578443A (en) * 1991-03-06 1996-11-26 Regents Of The University Of Minnesota DNA sequence-based HLA typing method
AU690131B2 (en) * 1993-07-26 1998-04-23 Variagenics, Inc. Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents
US5696076A (en) * 1994-06-22 1997-12-09 Human Genome Sciences, Inc. 5-lipoxygenase-activating protein II
EP0896633A2 (en) * 1996-05-06 1999-02-17 Brigham And Women's Hospital 5-lipoxygenase gene polymorphisms and their use in classifying patients
CA2321226C (en) * 1998-04-15 2011-06-07 Genset S.A. Genomic sequence of the 5-lipoxygenase-activating protein (flap), polymorphic markers thereof and methods for detection of asthma

Also Published As

Publication number Publication date
DE69933661T3 (de) 2012-01-26
US20050196752A1 (en) 2005-09-08
CA2321226A1 (en) 1999-10-21
US20070003971A1 (en) 2007-01-04
JP4472173B2 (ja) 2010-06-02
WO1999052942A3 (en) 2000-02-03
AU768721B2 (en) 2004-01-08
US6531279B1 (en) 2003-03-11
DE69933661T2 (de) 2007-08-23
US7494777B2 (en) 2009-02-24
ATE342918T1 (de) 2006-11-15
JP2002511242A (ja) 2002-04-16
DK1071710T4 (da) 2011-12-12
ES2272061T5 (es) 2012-02-24
DE69933661D1 (de) 2006-11-30
PT1071710E (pt) 2007-01-31
AU3164499A (en) 1999-11-01
US20090155806A1 (en) 2009-06-18
US7838241B2 (en) 2010-11-23
US7118869B2 (en) 2006-10-10
ES2272061T3 (es) 2007-04-16
EP1071710B1 (en) 2006-10-18
CA2321226C (en) 2011-06-07
EP1071710A2 (en) 2001-01-31
WO1999052942A2 (en) 1999-10-21
EP1071710B2 (en) 2011-11-02

Similar Documents

Publication Publication Date Title
DK1071710T3 (da) Genomisk sekvens for 5-lipoxygenase-aktiveringsproteinet (FLAP), polymorfe markörer deri og fremgangsmåder til påvisning af astma
DK1137943T3 (da) Fremgangsmåde til påvisning af cancer og reagenser
DK1439897T3 (da) Fremgangsmåder til adskillelse af sjældne celler fra væskeprøver
WO2002061659A3 (en) Computer-assisted means for assessing lifestyle risk factors
WO2004048933A3 (en) Methods for diagnosing rcc and other solid tumors
WO2003048300A3 (en) Methods of identifying cellular target molecules
ATE336591T1 (de) Nachweisverfahren für kurze sequenzvarianten
WO2004047623A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2002059379A3 (en) Methods for detecting, grading or monitoring an $i(h. pylori) infection
WO2000056924A3 (en) Genomic sequence of the purh gene and purh-related biallelic markers
WO2005027710A3 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
WO2000022122A3 (en) Genes, proteins and biallelic markers related to central nervous system disease
DE69939623D1 (de) Polymorphe marker von prostatakarzinom tumorantigen-1 (pcta-1)
WO2001063293A3 (en) Diagnosis and treatment of schizophrenia
AU2003233292A1 (en) Protein c polymorphisms
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof
AU2003265998A1 (en) Methods of cardiovascular disease assessment in an individual
TW200517502A (en) Methods for detecting Alzheimer's disease
AU2003294932A1 (en) Method for the detection of cancer
WO2002020835A3 (en) Genetic study
WO2004007719A8 (en) Use of sumo- and ubiquitin-modified pcna for detection and channeling of dna transaction pathways
WO2004048548A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2002090585A3 (en) Genetic polymorphism pattern of tgfb1 as marker for susceptability to renal disease
AU2001276674A1 (en) Diagnosis of liver cancer based on detecting sssa1 protein
PT1573059E (pt) Método de identificação e quantificação de proteínas, isoformas da enzima conversora de angiotensina i